Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study.

Kirby, Joslyn S; Okun, Martin M; Alavi, Afsaneh; Bechara, Falk G; Zouboulis, Christos C; Brown, Kurt; Santos, Leandro L; Wang, Annie; Bibeau, Kristen B; Kimball, Alexa B; Porter, Martina L

Kirby, Joslyn S; Okun, Martin M; Alavi, Afsaneh; Bechara, Falk G; Zouboulis, Christos C; Brown, Kurt; Santos, Leandro L; Wang, Annie; Bibeau, Kristen B; Kimball, Alexa B; Porter, Martina L.

Afiliación

Kirby JS; Department of Dermatology, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania. Electronic address: jkirby1@pennstatehealth.psu.edu.
Okun MM; Department of Dermatology, Fort Memorial Hospital, Fort Atkinson, Wisconsin.
Alavi A; Department of Dermatology, Mayo Clinic, Rochester, Minnesota.
Bechara FG; Department of Dermatology, Allergology and Venereology, Ruhr University Bochum, Bochum, Germany.
Zouboulis CC; Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany.
Brown K; Incyte Corporation, Wilmington, Delaware.
Santos LL; Incyte Corporation, Wilmington, Delaware.
Wang A; Incyte Corporation, Wilmington, Delaware.
Bibeau KB; Incyte Corporation, Wilmington, Delaware.
Kimball AB; Department of Dermatology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Porter ML; Department of Dermatology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts.

J Am Acad Dermatol ; 90(3): 521-529, 2024 Mar.

Article en En | MEDLINE | ID: mdl-37871805

Asunto(s)

Hidradenitis Supurativa; Humanos; Hidradenitis Supurativa/diagnóstico; Absceso; Janus Quinasa 1; Resultado del Tratamiento; Índice de Severidad de la Enfermedad; Método Doble Ciego

Palabras clave

DLQI; FACIT-F; HS; HiSCR; HiSQoL; IHS4; INCB054707; JAK1; JAK1 inhibitor; clinical trial; efficacy; hidradenitis suppurativa; itch; oral administration; patient-reported outcomes; placebo-controlled; povorcitinib; skin pain

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Hidradenitis Supurativa Límite: Humans Idioma: En Revista: J Am Acad Dermatol Año: 2024 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google